Zydus Lifesciences zooms as its arm inks definitive pact to acquire outstanding shares of Assertio
Zydus Lifesciences zooms as its arm inks definitive pact to acquire outstanding shares of Assertio is currently trading at Rs. 983.00, up by 44.05 points or 4.69% from its previous closing of Rs. 938.95 on the BSE.
The scrip opened at Rs. 965.20 and has touched a high and low of Rs. 984.20 and Rs. 960.15 respectively. So far 93551 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1059.00 on 19-Sep-2025 and a 52 week low of Rs. 835.85 on 02-Apr-2026.
Last one week high and low of the scrip stood at Rs. 998.65 and Rs. 890.00 respectively. The current market cap of the company is Rs. 98143.03 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 18.15% and 6.86% respectively.
Zydus Lifesciences’ subsidiary -- Zydus Worldwide DMCC (Zydus Worldwide) has signed a definitive agreement through its wholly owned acquisition subsidiary Zara Merger Sub Inc., (Zara) with Assertio Holdings, Inc. (Assertio), to acquire all outstanding shares of Assertio for $23.50 per share in cash representing total consideration of around $166.4 million on a fully-diluted basis, calculated using the treasury stock method. Zydus Worldwide, Zara and the company are collectively referred to as 'Zydus'.
The acquisition is expected to be completed in the financial year 2026-27 subject to customary conditions. Assertio is a U.S. based pharmaceutical company focused on specialty and oncology supportive-care therapies with its novel product ROLVEDON (eflapegrastim xnst), approved as BLA by USFDA for long-acting G CSF biologic for the prevention of febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy. The equity shares of Assertio are listed on Nasdaq with code ‘ASRT’.
This transaction has been approved by the Boards of Directors of both Zydus Worldwide and Assertio and it is structured as a tender offer to be followed by a merger, subject to customary closing conditions and regulatory approvals. This transaction will help Zydus to secure an immediate U.S. specialty oncology commercial footprint and use it as a platform to expand an oncology specialty portfolio. Assertio’s 170 plus community oncology accounts and buy-and-bill infrastructure offers a ‘ready-made’ base to build a broader oncology platform.
.jpg)
